RxDoctor Payments DataLook up a doctor →

Roberto Ferro Valdes, MD

Hematology & Oncology · Sioux Falls, SDNPI 1861780108

Payments from drug & device makers

$507,273in general payments, 2019–2025

Across 467 payments — averaging $1086.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$119K
  • Novartis$97K
  • Incyte Corporation$89K
  • AstraZeneca$76K
  • Takeda Pharmaceuticals U.S.A., Inc.$42K
  • Astellas Pharma US Inc$20K
  • plus $65K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC23$118,540
Novartis26$97,498
Incyte Corporation30$88,723
AstraZeneca(2 entities)90$75,845
Takeda Pharmaceuticals U.S.A., Inc.19$41,831
Astellas Pharma US Inc32$20,300
ADC Therapeutics America, Inc.2$17,221
AbbVie24$12,175
Gilead(2 entities)11$7,312
GSK11$4,530
Merck17$4,113
Genentech, Inc.3$3,672
E.r. Squibb & Sons, L.L.C.22$3,423
Sanofi10$2,888
Dova Pharmaceuticals4$1,800
Seagen Inc.5$1,585
Bristol Myers Squibb9$1,432
Epizyme, Inc.1$1,250
Genentech USA, Inc.22$436
Johnson & Johnson(2 entities)9$260
Pfizer15$234
Ipsen Biopharmaceuticals, Inc4$179
Amgen10$163
Agios Pharmaceuticals, Inc.2$154
Karyopharm Therapeutics Inc.2$153
Eli Lilly1$139
Adaptive Biotechnologies Corporation1$135
Eisai Inc.7$126
Beigene USA, Inc.1$125
Lilly USA, LLC8$122
Bayer4$108
Morphosys, US Inc.2$102
Daiichi Sankyo Inc.4$89
Regeneron Healthcare Solutions, Inc.2$73
Taiho Oncology, Inc.3$50
Pharmacyclics LLC, An Abbvie Company3$48
Invivyd Inc1$31
Exelixis Inc.1$27
Array Biopharma Inc2$26
Lexicon Pharmaceuticals, Inc.2$25
Syndax Pharmaceuticals, Inc.1$23
Beone Medicines USA, Inc.1$22
Sumitomo Pharma America, Inc.1$22
Boehringer Ingelheim1$20
Tersera Therapeutics LLC1$19
Recordati_rare_diseases_inc.1$19
Rigel Pharmaceuticals, Inc.1$18
Apellis Pharmaceuticals, Inc.1$17
Mirati Therapeutics, Inc.1$16
Jazz Pharmaceuticals Inc.1$16
AMAG Pharmaceuticals, Inc.1$15
AVEO Pharmaceuticals, Inc.1$15
Blueprint Medicines Corporation1$14
Novocure Inc.1$14
Acrotech Biopharma Inc.1$14
Genmab U.S., Inc.1$13
Secura Bio, Inc.2$13
Puma Biotechnology, Inc.1$12
Organon1$10
Sirtex Medical Inc1$9

How this compares

$507,273 in reported general payments places this provider in the 65th percentile of 28 hematology & oncology providers in South Dakota.

See all hematology & oncology providers in South Dakota

Medicare billing

Part B allowed, 2024
$3,415,249
Medicare patients
527
Services billed
127,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →